Is Cd11c and Fmc7 Negativity in Chronic Lymphocytic Leukemia Poor Prognostic?
- 10 Downloads
Chronic lymphocytic leukemia (CLL) is a common hematological malignancy. This study is aimed to investigate the prognostic effect of clinic, laboratory and flow cytometric analysis in CLL patients. Newly diagnosed 55 CLL cases were divided into two groups, as stable disease (Group 1) and progressive disease (Group 2). Group 1 included those who did not require any treatment since diagnosis and those who did not progress after receiving the first step anti CLL treatment. Group 2 included the patients who received ≥ 2 steps treatment. The relation between the two groups was analyzed statistically in terms of clinical, laboratory and flow cytometric findings. Twenty patients (36.3%) required treatment at the time of diagnosis, four patients (3.8%) received first-line treatment during follow-up and 31 (56.3%) patients were followed without any treatment. Thirteen patients required second step treatment after a median of 26.3 months. The risk of progression was found to be increased 5-fold (p = 0.015) in the CD38 positive patient group, 4.2-fold (p = 0.0147) in the FMC7 negative patient group and 2.8-fold in the CD11c negative patient group. FMC 7 negativity decreased total survival 5.9-fold (p = 0.051). Unlike similar publications, we found that patients with CD11c or FMC7 negativity were in a higher need for ≥ 2 step treatment. This suggests that CD11c or FMC7 negativity may be used as a poor prognostic marker in CLL.
KeywordsCLL Flowcytometry FMC7 CD11c
The authors declared that this study has received no financial support.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 2.Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS (1975) Clinical staging of chronic lymphocytic leukemia. Blood 46(2):219Google Scholar
- 4.Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H et al (2008) International workshop on chronic lymphocytic leukemia, guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the international workshop on chronic lymphocytic leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111(12):5446CrossRefGoogle Scholar
- 5.Diehl LF, Ketchum LH (1998) Autoimmune disease and chronic lymphocytic leukemia: autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia. Semin Oncol 25(1):80Google Scholar
- 7.Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al (2008) World Health Organization classification of tumours of haematopoietic and lymphoid tissues, 4th edn. IARC Press, LyonGoogle Scholar
- 8.Rai KR, Montserrat E (1987) Prognostic factors in chronic lymphocytic leukemia. Semin Hematol 24(4):252–256Google Scholar
- 12.Gentile M, Mauro FR, Rossi D, Vincelli I, Tripepi G, Recchia AG et al (2014) Italian external and multicentric validation of the MD Anderson Cancer Center nomogram and prognostic index for chronic lymphocytic leukaemia patients: analysis of 1502 cases. Br J Haematol 167(2):224–232CrossRefGoogle Scholar
- 15.Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL et al (1999) Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94(6):1840Google Scholar
- 19.Wormsley SB, Baird SM, Gadol N, Rai KR, Sobol RE (1990) Characteristics of CD1 lc + CDS + chronic B-cell leukemias and the identification of novel peripheral blood b-cell subsets with chronic lymphoid leukemia ımmunophenotypes. Blood 76:123–130Google Scholar
- 21.Hamed NAM (2017) Treatment of chronic lymphocytic leukemia in the elderly, Alexandria University, Egypt Submission 10 Mar 2017; Published: 16 Mar 2017Google Scholar
- 23.Epstein AL, Marder RJ, Winter JN, Stathopoulos E, Chen FM, Parker JW et al (1987) Two new monoclonal antibodies, Lym-1 and Lym-2, reactive with human B-lymphocytes and derived tumors, with immunodiagnostic and immunotherapeutic potential. Cancer Res 47(3):830Google Scholar
- 28.Reddy P, Dabbas B, Gama M, Kocher T, Drum H, Taylor J et al (2012) FMC-7 expression identifies phenotypically atypical chronic lymphocytic leukemia with distinct clinical and molecular genetic features. Blood 120(21):2478Google Scholar
- 32.Meyerson HJ, Dalia SM, Koc ON, Fu P, Cocco AE (2004) Cellular expression of CD23, CD71, and CD38 are ındependent prognostic variables in B-cell chronic lymphocytic leukemia. Blood 104(11):47–5313Google Scholar